The forecasted sales of pharmaceutical preparations targeting the central nervous system and sense organs in the U.S. from 2024 to 2028 indicate steady growth. Sales are projected to increase annually from $37.291 billion in 2024 to $39.375 billion in 2028. Although specific year-on-year percentage variations were not provided, the consistent upward trend suggests a steady market demand. The compounded annual growth rate (CAGR) over the five-year period reaffirms this steady expansion.

Future trends to watch for include:

Advancements in biotechnology and personalized medicine potentially impacting market size and composition.
Regulatory changes and healthcare policies affecting pharmaceutical pricing and accessibility.
Emerging mental health awareness driving increased demand for CNS-related therapies.